A number of large randomised controlled trials have shown that angiotensin-converting enzyme (ACE) inhibitors, compared with placebo or other blood pressure-lowering drugs, improve coronary heart disease outcomes (fatal and nonfatal myocardial infarction, and coronary revascularisation) in diverse patient groups, e.g. in primary and secondary prevention, those with and without left ventricular dysfunction, and among hypertensive and non-hypertensive
Introduction
It is 25 years since the first angiotensinconverting enzyme (ACE) inhibitor was launched as a third-or fourth-line treatment for difficult-tocontrol hypertension. 1 Over the last quarter century a series of large clinical trials has extended the use of ACE inhibitors (ACE-Is) into heart failure, 2, 3 and provided evidence that ACE-I based therapy, as well as lowering blood pressure (BP), improves cardiovascular (CV) function, target organ damage and clinical outcomes in high-risk patients with atherosclerotic disease, 4 e.g. those with previous myocardial infarction (MI) 5, 6 and patients with diabetes-related microvascular complications such as proteinuria and retinopathy. [7] [8] [9] [10] In the meta-analysis published by the BP Lowering Treatment Trialists collaboration in 2003, which included the Heart Outcomes Prevention Evaluation (HOPE) study 4 and Quinapril Ischaemic Event (QUIET) 12 trial, ACE-I based regimens reduced the risk of coronary artery disease (CAD) events by 20% (CI 12-27%) compared with placebo, but for regimens targeting lower BP goals there was less certainty about benefit in terms of CAD outcomes (5%, CI -11-19%). 11 Since that meta-analysis, there have been several placebo-controlled trials of ACE-I therapy in lower-risk populations, e.g. patients with stable CAD without heart failure, [12] [13] [14] and trials comparing ACE-I-calcium channel blocker (CCB) combinations with conventional antihypertensive agents in the primary 15 and secondary 16 prevention of CAD.
An updated meta-regression analysis has provided further information about the effect of ACE-I on CAD outcomes. 17 This analysis included five major trials appearing since 2003: European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA), 13 International Verapamil SR/ Trandolapril (INVEST) study, 16 A Coronary disease Trial Investigating Outcome with Nifedipine GITS (ACTION), 18 Comparison of Amlodipine vs Enalapril to Limit Occurrences of Thrombosis (CAMELOT) trial 19 and Prevention of Events with Angiotensin-Converting Enyzme inhibition (PEACE) trial 14 (table 1) . All five of these studies were secondary prevention trials in patients with known CAD, and four of the trials were placebocontrolled. The analysis concluded that ACE-Is are marginally better than CCB in CAD prevention, whereas the opposite is true for stroke (table 2) . 17 In addition, a meta-analysis of the HOPE, PEACE and EUROPA data concluded that there are clear benefits of ACE-I therapy in reducing mortality, reinfarction and stroke in patients with vascular disease and normal left ventricular (LV) function. 20 Although the meta-analyses of ACE-I therapy have been informative and rigorous with respect to cardiac outcomes, the conclusions often overlook significant and unexplained differences in major end points, baseline CV risk, changes in BP, mechanistic considerations and key differences in study design. Thus, the purpose of this review is to compare and discuss key features of these trials (table 1) , explore the mechanisms and clinical determinants of CAD prevention with ACE-I therapy, and to highlight important questions that remain unclear.
Clinical trials investigating whether ACE inhibitor therapy improves CAD outcomes: a mixed picture

Placebo-controlled trials of ACE inhibition
In patients with MI complicated by heart failure or LV dysfunction, there is consistent evidence that ACE-I therapy improves survival and reduces the risk of further MI. 5, 6 For example, in the Survival And Ventricular Enlargement (SAVE) trial captopril reduced the risk of recurrent MI by 25%, 2 and similarly in the Acute Infarction Ramipril Efficacy (AIRE) trial the ACE-I conferred a 27% reduction in all-cause mortality. 5 In patients without LV dysfunction, the HOPE study 4 recruited a high-risk patient population: those over 55 years of age with a history of cardiovascular disease and/or diabetes plus one other risk factor (n=9,297). Add-on treatment with ramipril compared with placebo reduced the primary composite end point (MI, stroke or CV death) by 22% ( figure 1c ). In addition, there were significant relative risk reductions for MI (20%), stroke (32%), coronary revascularisation (15%) and worsening angina (11%), but ramipril had no significant effect on hospitalisation for heart failure. 4 EUROPA recruited a lower-risk and lessheterogeneous population of patients with stable CAD (n=12,218, aged 26-6 years, irrespective of their risk factor profile). 13 A diagnosis of CAD required evidence of prior MI (> 3 months before screening) or coronary revascularisation (surgery 
Figure 1
Placebo-controlled trials of ACE-Is in patients with stable CAD have not been entirely consistent. These figures show the results for the primary end points in the HOPE, EUROPA and PEACE studies. In HOPE, the primarty end point was a composite of MI, stroke or death from CV causes. 4 In EUROPA, the primary end point was a composite of CV death, non-fatal MI and cardiac arrest with successful resuscitation. 13 In the PEACE study, the primary end point was death from CV causes or non-fatal MI death. Reproduced with permission, The PEACE trial investigators. or angioplasty), or coronary angiographic evidence of > 70% stenosis in one or more major vessels (men with cardiac symptoms and a positive stress test were also enrolled). Mean age was 60 years, and 27% of patients had documented hypertension at baseline (defined as BP > 160/95 mmHg and/or use of antihypertensive therapy). The primary end point in EUROPA was a composite of CV death, nonfatal MI and cardiac arrest with successful resuscitation; mean follow-up was 4.2 years. Perindopril 8 mg o.d. as add-on therapy to existing medications resulted in a 20% reduction in the primary end point (95% CI 9-29%) (figure 1a); a 24% reduction in fatal and non-fatal MI; and a 39% reduction in new onset heart failure. The incidence of the primary end point was 8% in the perindopril group and 10% in the placebo group (p=0.0003). 13 Total mortality was 11% lower in perindopril-treated patients but this did not achieve significance. Stroke rates were low in the EUROPA study but not different between the perindopril and placebo groups (1.6% vs. 1.7%, NS). The difference in BP between the two groups was 5/2 mmHg. Outcome was improved in all prespecified subgroups, in particular in all age groups and among those with and without a history of hypertension, diabetes or previous MI. 13 The PEACE trial was a placebo-controlled study of trandolapril 4 mg daily in 8,290 patients with stable CAD and normal left ventricular function (age > 50 years, ejection fraction > 40%, and prior history of MI or coronary revascularisation or > 50% stenosis of a vessel on coronary angiography). 14 The primary end point was a composite of CV death, non-fatal MI and revascularisation. Mean age at baseline was 68 years, 55% of patients had suffered a prior MI and 72% had undergone at least one coronary revascularisation procedure. Hypertension was documented at baseline in 45% of patients. Median follow-up was 4.8 years. The incidence of the primary end point was 22.5% in the placebo group and 21.9% in the trandolapril group (hazard ratio 0.96 in the ACE-I group, 95% CI 0.88-1.06, p=0.43) (figure 1b). Adjustment for baseline characteristics (e.g. age, prior MI or stroke, or diabetes status) had no effect on the results: trandolapril had no significant effect on any of the primary or secondary end points. 14 QUIET was a smaller placebo-controlled study designed to test the hypothesis that quinapril 20 mg o.d. would reduce the risk of ischaemic events (cardiac death, resuscitated cardiac arrest, non-fatal MI, revascularisation or hospitalisation for unstable angina) and the angiographic progression of CAD in patients without LV systolic dysfunction. 12 A total of 1,750 patients (aged 18-75 years; all with a prior history of angioplasty or atherectomy) received quinapril or placebo for a mean follow-up of 27 months. Hypertension was documented in 47% of patients, and type 2 diabetes in 16%, at baseline. Importantly, patients with previous surgical revascularisation, those receiving lipid-lowering therapy and patients with low density lipoprotein-cholesterol (LDL-c) levels > 4.3 mmol/L were excluded from the study. The number of ischaemic events in the quinapril group (338) and the placebo group (329) were similar, relative risk 1.04 (95% CI 0.89-1.22, p=0.6). 12 Similarly, the time to first major cardiac ischaemic event was not significantly different between the two groups. A total of 602 angioplasty procedures were performed during the period of study follow-up: 312 among placebo-treated patients and 290 among quinapril-treated patients. In the angiographic substudy, 47% of quinapriltreated patients and 49% of placebo-treated patients were classified as progressors (p=0.71). 21
Meta-analysis of placebo-controlled trials
A systematic review of the HOPE, EUROPA and PEACE trials has been undertaken to quantify CV outcomes and total mortality in the combined cohort of 29,805 patients who had stable vascular disease without LV systolic dysfunction. 22 ACE-I therapy significantly reduced all-cause mortality (7.8% vs. 8.9%, p=0.0004), CV mortality (4.3 vs. 5.2%, p=0.0002), non-fatal MI, stroke, heart failure and coronary bypass surgery. There was no treatment effect on percutaneous coronary intervention. There was an 18% relative risk reduction in the composite outcome of CV mortality, non-fatal MI and stroke (odds ratio 0.82 [CI 0.76-0.88], p<0.0001). Thus, for every 1,000 patients treated over 4.5 years 21 will not have one of these serious outcomes.
The results of this meta-analysis confirm that the effects of ACE-I therapy in patients with stable vascular disease are broadly similar to the effects previously reported in patients with heart failure or LV systolic dysfunction. Of course, patients with heart failure are at higher absolute CV risk, but the risk reduction of 21% for combined CV mortality, non-fatal MI and stroke is similar to the figure of 18% in patients without heart failure. 22 The only differences were in stroke and revascularisation. In the ACE-I trials in patients with heart failure (+ recent MI), there was no effect on stroke. This may be due to lower pre-treatment BP, but in HOPE, EUROPA and PEACE there was a clear benefit of ACE-I therapy on stroke end points. 22
Trials comparing dual ACE inhibitor-calcium channel blocker therapy with other BPlowering combinations
The INVEST study sought to compare mortality and morbidity outcomes in patients with hypertension and stable CAD treated with a calcium antagonist strategy or a non-calcium Similarly, there were no differences in time to nonfatal MI or stroke. 16 Fatal and non-fatal MI occurred in 4.01% of the calcium-antagonist-based therapy group and 3.90% of the non-calciumantagonist-based therapy group. The primary end points were no different between treatment groups in high-risk versus low-risk patient populations, and in those with or without prior MI or prior coronary revascularisation. 16 Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT) was a randomised controlled trial of the prevention of coronary heart disease and other vascular events by BP and cholesterol lowering in a factorial study design. The BP-lowering arm of ASCOT (ASCOT-BPLA) sought to compare the effects of a standard antihypertensive regimen (the betablocker atenolol 50-100 mg daily +/bendroflumethiazide 1.25-2.5 mg daily) with a more contemporary regimen (the CCB amlodipine 5-10 mg o.d. +/-the ACE-I perindopril 4-8 mg o.d.) on non-fatal MI and fatal CA events (n=19,527). 15 ASCOT-BPLA recruited patients with hypertension aged 40-79 years who had three or more risk factors but no prior history of MI or clinical evidence of CAD at baseline. In October 2004, the data safety monitoring board recommended that ASCOT-BPLA be stopped on account of concerns that those patients receiving atenolol/thiazide would continue to be disadvantaged compared with the amlodipine-perindopril group. Trial closure began in December 2004 after a median followup of 5.4 years. 15 Overall, BP was lowered by 28/16 mmHg and there were early differences in favour of a greater BP-lowering response with amlodipine/ perindopril (e.g. BP was 5.9/2.4 mmHg lower at three months). The BP differences between groups reduced over time, and the mean difference in BP between the two groups over the course of the trial was 2.7/1.9 mmHg. 15 Compared with the atenolol/thiazide group, amlodipine/perindopril resulted in a 10% (nonsignificant) reduction in the primary end point; a 23% reduction in fatal and non-fatal strokes (p<0.0003); and a 16% reduction in all CV events and revascularisation procedures (p<0.005). CV mortality and total mortality were 24% and 14% lower, respectively, in the amlodipine/perindopril group (p<0.005), and the incidence of new-onset diabetes was reduced by 30% in the ACE-I-calcium antagonist treatment arm. 15 Pulse Pressure was the best predictor of CV events.
Two further end points, defined post hoc based on end points used in previous large trials, also achieved statistical significance in favour of the amlodipine/perindopril group: (1) the primary end point + coronary revascularisation procedures (14% risk reduction, p<0.0058), and (2) CV death + MI + stroke (16% risk reduction, p<0.0003). 15 Further analysis of ASCOT-BPLA has focused on the possible explanations for the different CV event rates in the two treatment groups. 23 Were the differences in BP sufficient to account for the observed differences in CV outcome? The accumulated mean in-trial difference in systolic blood pressure (SBP) was 2.7 mmHg in favour of the amlodipine-based regimen, but on the basis of observational epidemiology this difference in BP would translate into 8% fewer coronary heart disease (CHD) events and 11% fewer strokes. These figures contrast with the actual differences of 14% and 23%, respectively, reported in ASCOT-BPLA. In addition, there was no temporal link between the size of the BP difference and the differences in CHD and stroke events. 23 Allocation to the amlodipine/perindopril treatment regimen was associated with a higher pulse rate, and beneficial effects on body weight, serum high density lipoprotein-cholesterol (HDL-c), creatinine and fasting blood glucose. 15 In particular, differences in HDL-c had the biggest effect on differences in the rates of coronary events. 23 For stroke, multivariate analysis that included biochemical measurements had little or no added benefit after adjustment for BP. These analyses, however, could only account for 40-50% of the variability in CHD and stroke events, which implies that other factors, yet to be identified, may explain a substantial part of the benefit attributable to the amlodipine/perindopril regimen. Statistical adjustments for in-trial differences in BP are hampered by a number of limitations, and therefore small differences in BP should not be underestimated in the interpretation. 
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Cardioprotective effect of ACE inhibitors in CAD: interpretation, mechanisms and clinical determinants
What clinical, mechanistic and/or pharmacological factors account for these mixed results? A number of important aspects of these trials merit further discussion. Firstly, the importance of small in-trial differences in BP may have previously been underestimated. Average differences in BP of 1-3 mmHg between treatment arms were initially disregarded as clinically irrelevant, but more recently there has been a wider understanding and acknowledgement that such differences in BP, maintained over several years, might substantially account for the observed differences in outcome. For example, in the recent Felodipine EVEnt Reduction (FEVER) trial, add-on therapy with a low dose of felodipine produced a sustained reduction in BP of only 4/2 mmHg but this was sufficient to provide clinically important reductions in various CV outcomes, including a 35% reduction in all cardiac events. 24
Is the cardioprotective effect dependent upon the level of CHD risk?
In general, the benefits of ACE-I therapy in the HOPE and EUROPA studies were consistent across a range of patient groups and risk categories, e.g. those with and without diabetes. 25, 26 Further analysis of the EUROPA database has compared the primary end point reductions for perindopril and placebo according to different tertiles of CV risk 27 (figure 2). The authors analysed the association between major CV events (death or MI) and prospectively defined patient characteristics at baseline. By multivariate analysis, the following patient characteristics emerged as the most powerful independent risk indicators: age > 65 years (RR 1.15), male gender (RR 1.2), angina (RR 1.7), prior MI (RR 1.40), prior stroke or peripheral arterial disease (RR 2.0), diabetes (RR 1.80) and smoking (RR 1.4). These risk factors were amalgamated into a single risk score for individual patients, and the cardioprotective effect of perindopril was consistent among highintermediate-and low-risk patients ( figure 2) . Thus, risk reduction with the ACE-I was not modified by absolute level of risk. 27 It was suggested that the lack of effect of trandolapril in the PEACE study might be due to a lower risk patient population. 14 This seems difficult to reconcile with a number of observations. First, 72% of patients in the PEACE study had undergone coronary revascularisation at baseline (vs. 40% in HOPE and 54% in EUROPA). Secondly, post hoc analysis of the PEACE outcome data showed that death from CV causes, non-fatal MI or cardiac arrest occurred in 8.6% of placebo-treated patients. 14 This is very similar to the figure of 9.4% for death or MI among placebo-treated patients in the medium-risk group (patients in the second tertile) of the EUROPA cohort 27 (figure 2) . Thirdly, the baseline characteristics of patients in the PEACE study were broadly similar to those in EUROPA, and in many respects indicated at least a similar spectrum of CV risk. For example, mean age was 64 years (vs. 60 yrs in EUROPA), 17% had diabetes (vs. 12% in EUROPA), and 70% had stable angina (vs. 19% in EUROPA).
Is the cardioprotective effect mainly or solely attributable to BP reduction?
This has been a source of great debate and controversy as further post hoc analyses and commentaries have emerged. [28] [29] [30] For example, although the difference in office BP between ramipril and placebo-treated patients in the HOPE study amounted to only 3.3/1.4 mmHg, 4 a small substudy using ambulatory BP (ABP) in 38 HOPE participants with peripheral arterial disease reported that ramipril lowered 24-hour ABP by 10/4 mmHg after one year. 29 The effect on ABP was mainly due to nighttime BP reduction; ramipril 10 mg was administered at bedtime in the HOPE study. This finding has created ongoing uncertainty about the extent to which BP reduction with ACE inhibition contributes to cardioprotection. 30 Certainly the benefits observed with ramipril in the HOPE study were far greater than would be 
Figure 2
The baseline characteristics of the 12 More recently, it has become clear that BP reduction among patients with stable CAD does not necessarily translate into fewer CV events. The ACTION trial randomised 7,665 patients with stable symptomatic CAD to nifedipine GITS (gastrointestinal therapeutic system) 60 mg o.d. or placebo as add-on to usual therapy. 18 The patient population was very similar to those in the ACE-I trials (HOPE, PEACE and EUROPA) in that average age was 63 years; 15% had diabetes; baseline BP was 137/79 mmHg; and 45% had previous coronary revascularisation. Mean follow-up was 4.9 years, and the primary end point was major CV event-free survival, defined as time to occurrence of the first of the following events: death from any cause, acute MI, refractory angina, onset of new overt heart failure, stroke and peripheral revascularisation. 18 Treatment with nifedipine increased mean heart rate (HR) during follow-up by 1 bpm, and decreased BP, on average, by 6/3 mmHg. However, primary end point rates were almost identical in the two groups: 4.60 per 100 patientyears for nifedipine and 4.75 per 100 patientyears for placebo (0.97, CI 0.88-1.07, p=0.54). Nifedipine GITS did have a positive effect on two out of three prespecified secondary combined end points: the combined rate of death, major CV events, revascularisation and coronary angiography was reduced by 11%, although this was due almost entirely to fewer coronary angiograms; and any vascular event was reduced by 9%, due mainly to fewer coronary angioplasties and revascularisation procedures. 18 On the other hand, the recent FEVER study, also using a dihydropyridine CCB, did show a major reduction in cardiac events in association with a small difference in BP with felodipine. 24 The level of CV risk among patients in the ACTION trial was very similar to that in EUROPA (mortality rate in the placebo group was 1.53 per 100 patient-years of follow-up), and the difference in BP between active and placebo groups was also similar in the two trials: 6/3 mmHg (ACTION) vs. 5/2 mmHg (EUROPA). Yet, whereas the ACE inhibitor had a major effect on CV outcome, in the ACTION trial a similar difference in BP had no effect on fatal or nonfatal CV events. The FEVER trial, however, using a different dihydropyridine calcium antagonist did improve CAD event rates with similar (4/2 mmHg) reductions in BP. 24 Whether the small increase in HR among patients treated with nifedipine offset the benefits of BP reduction merits further consideration. Recent studies have highlighted the prognostic importance of resting HR in patients with hypertension and MI. 31, 32 In 15-year follow-up of the Coronary Artery Surgery Study, patients with CAD in the top quintile of resting HR had significantly higher risks for all-cause (RR 1.32) and CV (RR 1.31) mortality. 33 The predictive power of HR was evident even after adjustment for other clinical variables, and in particular HR was of prognostic importance in patients with and without evidence of left ventricular dysfunction. 33 A further recent analysis of the ACTION trial has stratified patients according to hypertension status at baseline. 34 A total of 52% of the participants were hypertensive, and in this subgroup nifedipine GITS significantly reduced the combined incidence of all-cause mortality, MI, refractory angina, heart failure, stroke and peripheral revascularisation by 13%. Although this was a post hoc analysis, and the division of patients into hypertensive and normotensive groups was arbitrarily based on BP (irrespective of treatment), the study appears to show that hypertensive patients with CAD obtained more benefit than the study population overall. 35 A recent analysis of data from the EUROPA study has provided further information about the relationship between CV benefit and BP reduction. 36 The effect of perindopril was not influenced by baseline BP (table 3) , although the CV benefit tended to be greater in those patients with lower SBP. In addition, the authors examined BP data for all patients while receiving perindopril 8 mg o.d. during the preliminary four week run-in period. SBP remained unchanged after four weeks in 3,645 patients, and in this subgroup the relative risk reduction for perindopril (17.7%) was comparable to that (20.5%) for patients in whom there was a greater effect of perindopril on BP during the run-in period. 36 Thus, it was concluded that the treatment effect of the ACE-I was influenced neither by baseline BP nor the initial BP response to perindopril during the run-in period. Review Table 3 The effect of ACE-I therapy in the EUROPA study was not influenced by baseline BP or the magnitude of BP reduction. In the ASCOT-BPLA study, the benefits of the CCB-ACE-I combination, especially on cardiac event rates, were far greater than could be explained by modest in-trial differences in office BP. 23 Metabolic differences, e.g. higher HDLcholesterol levels, were identified among the amlodipine/perindopril treated patients as a possible contributor to the better CHD outcomes, but other haemodynamic factors that were not measured in the study could still be involved, e.g. BP variability or differences in central pressure, particularly since pulse pressure was the most powerful predictor of CV events. 15
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Are the differences between trial results related to differences in background therapy?
The major ACE-I trials have been conducted over a 15-year timescale during which there have been enormous changes in medical and surgical approaches to treatment of high-risk patients with CAD. ACE-I therapy has been added to a background of 'usual care', and patterns of drug use (especially statins, beta-blockers, BP-lowering drugs and antiplatelet therapy) have changed significantly with each major trial and in the course of each trial. For example, in the earliest of these trials, the HOPE study (recruitment in 1993-1995) , only 28% of patients were on a lipid-lowering drug at baseline; 39% were on beta-blockers and 75% were on aspirin or another antiplatelet agent. 4 By the time the EUROPA study was conducted (recruitment 1997-2000) , baseline use of antiplatelet therapy had risen to 92%, lipidlowering therapy was 57%, and beta-blockers 62%. The PEACE study was conducted during a similar period (recruitment 1996-2000) , and baseline use of antiplatelet therapy was 90%, lipid-lowering therapy 70%, and beta-blockers 60%. 4 The higher use of lipid-lowering drugs and history of prior coronary revascularisation in the baseline data of the PEACE study no doubt reflects differences between North American and European practice (PEACE was conducted in the USA, Canada and Italy, while the EUROPA study was conducted mainly in Europe).
In the HOPE and EUROPA studies there was no evidence that ACE-I benefit was confined to those patients not taking other forms of CV therapy or in whom background treatment was suboptimal. For example, ramipril had a significant effect among the subgroup of patients already taking a beta-blocker (23% risk reduction in the primary end point), 4 and in EUROPA perindopril was equally effective in reducing the primary end point in key subgroups of patients, e.g. those on lipid lowering drugs (16% relative risk reduction), beta-blockers (25% relative risk reduction) and those on combination therapy with antiplatelet, beta-blocker and lipid-lowering agents (21.5% relative risk reduction). 13
Is CAD prevention with ACE inhibitors related to specific pharmacological mechanisms or pharmacokinetic differences?
The dose, timing and duration of therapy, as well as the pharmacological profile of the ACE-I, may be important in the light of the observed differences in outcome between the major clinical trials. Most patients assigned to ACE-I therapy in the HOPE and EUROPA studies were rapidly titrated to the target doses of ramipril 10 The disease-modifying effects of ACE inhibition on coronary atherosclerosis may well include an effect on the vessel wall, endothelial function and plaque stability. More than 90% of ACE is located within tissues rather than in the plasma, and ACE-Is vary in their lipophilicity and tissue penetration. 38, 39 ACE-Is with higher tissue localisation and greater tissue ACE inhibition include ramipril, quinapril, perindopril and benazepril. A small case-control study showed no benefit from taking a highly tissue active ACE-I in terms of risk of first non-fatal MI, 39 but a larger retrospective analysis of this has compared CV outcomes with seven different ACE-Is. 40 These studies have several weaknesses, but a total of 7,512 patients (1996) (1997) (1998) (1999) (2000) were commenced on one of the following ACE-Is within 30 days of hospital admission with acute MI: enalapril, captopril, fosinopril, lisinopril, perindopril, quinapril or ramipril. CV outcomes at one year showed significant differences between ACE-Is in their cardioprotective effects. 41 In particular, ramipril and perindopril were associated with the lowest mortality.
Endothelial dysfunction and oxidative stress are independent predictors of CV events, 42 and bradykinin preserves endothelial function via increased cellular expression of nitric oxide synthase (NOS). Abundant amounts of ACE are present in endothelial cells, and ACE-I have been shown to improve coronary artery endothelial function. 37, [42] [43] [44] Thrombosis and platelet aggregation in coronary vessels is also modulated by Ang II, and there is evidence that ACE-I improve the fibrinolytic balance. 45 A major substudy of the EUROPA trial, PERTINENT trial (PERindopril Thrombosis InflammatioN Endothelial dysfunction and Neurohormonal activation), should provide additional information in this area. 46 In PERTINENT, endothelial tissue was isolated from healthy volunteers and EUROPA patients to provide quantitative analysis of various markers of endothelial function, e.g. endothelial NOS, Ang II, bradykinin, the cytokine tumour necrosis factor-α (TNF-α), and von Willibrand factor (vWF), a marker of endothelial cell damage. 46 Treatment with perindopril resulted in a significant reduction in vWF and D-dimer at one year. In addition, the prognostic significance of vWF was confirmed: there was a significant difference in survival between those patients with high, versus those with low, levels of vWF. Levels of C-reactive protein, however, had no prognostic relationship to outcome. 46 A recent post hoc analysis of the HOPE data set has focused on changes in serum potassium as a possible mechanism of ACE-I induced cardioprotection. 46 Among the HOPE study cohort one month after randomisation there were 692 patients with serum K + > 5.0 mM and 137 patients with serum K + < 3.5 mM (thresholds defining hyper-and hypokalaemia, respectively).
In patients with hyperkalaemia, the primary event rate was unchanged compared with normokalaemia (15.5 vs. 15.7%, respectively), but with hypokalaemia the primary event rate was higher (22.6% vs. 15.5%, respectively, p=0.023). The benefit of ramipril on CV outcomes was independent of serum K+, but ramipril reduced hypokalaemia in the entire cohort (1.15% vs. 1.86% with placebo, p=0.005), and especially among patients taking diuretics. 47
Conclusions
There is a large body of evidence from randomised controlled trials showing that ACE-Is have important clinical benefits over other BPlowering drugs in terms of reducing the risk of new or recurrent CAD events and the need for coronary revascularisation. This evidence applies to patients with preserved LV function, as well as those with heart failure, and applies to hypertensive and non-hypertensive subjects covering a broad range of absolute CV risk. There are, however, curious differences between the trials, e.g. not all ACE-Is have consistently shown benefits, 14 and the underlying mechanisms remain unclear. While small differences in BP may have been under-estimated, metabolic and/or haemodynamic factors may also contribute to the clinical benefit of ACE inhibition especially with respect to CAD prevention. 
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